Medivation Inc. (NASDAQ:MDVN) reached a new 52-week high during trading on Thursday . The company traded as high as $62.98 and last traded at $62.52, with a volume of 707,895 shares trading hands. The stock had previously closed at $62.33.

A number of research firms have commented on MDVN. Credit Suisse Group AG reiterated a “buy” rating on shares of Medivation in a research note on Saturday, April 2nd. Cowen and Company reiterated a “hold” rating on shares of Medivation in a research note on Sunday, April 17th. Maxim Group increased their price target on Medivation from $47.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, May 5th. Barclays PLC reiterated a “buy” rating on shares of Medivation in a research note on Sunday, May 8th. Finally, Canaccord Genuity reiterated a “hold” rating on shares of Medivation in a research note on Wednesday, April 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Medivation has an average rating of “Buy” and a consensus price target of $71.76.

The company has a market cap of $10.30 billion and a PE ratio of 42.00. The company has a 50-day moving average price of $60.06 and a 200 day moving average price of $47.11.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by $0.12. During the same period in the previous year, the company posted $0.17 earnings per share. The business earned $182.50 million during the quarter, compared to analysts’ expectations of $197.01 million. The firm’s revenue was up 41.3% compared to the same quarter last year. Analysts forecast that Medivation Inc. will post $1.30 EPS for the current year.

In other Medivation news, SVP Andrew Kenneth William Powell sold 2,578 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $60.42, for a total transaction of $155,762.76. Following the transaction, the senior vice president now owns 28,517 shares in the company, valued at approximately $1,722,997.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Rick Bierly sold 10,340 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $59.76, for a total value of $617,918.40. Following the transaction, the chief financial officer now owns 35,059 shares in the company, valued at approximately $2,095,125.84. The disclosure for this sale can be found here.

A number of institutional investors have added to or reduced their stakes in MDVN. Advisors Asset Management Inc. boosted its position in Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 3,688 shares during the last quarter. TD Asset Management Inc. boosted its position in Medivation by 9.5% in the fourth quarter. TD Asset Management Inc. now owns 28,804 shares of the biopharmaceutical company’s stock valued at $1,392,000 after buying an additional 2,500 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. boosted its position in Medivation by 7.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. now owns 29,559 shares of the biopharmaceutical company’s stock valued at $1,429,000 after buying an additional 1,979 shares during the last quarter. Andra AP fonden boosted its position in Medivation by 19.5% in the fourth quarter. Andra AP fonden now owns 30,600 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 5,000 shares during the last quarter. Finally, Schroder Investment Management Group acquired a new position in Medivation during the fourth quarter valued at about $1,710,000.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.